COVID-19: MACH Response
Our partners and especially our health services face unprecedented challenges over the next few months. The research response to COVID-19 is second only in importance to the clinical care challenges posed by the epidemic. The MACH has responded by helping our health services and research institutes lead the fight-back by supporting highest priority COVID-19 research.
Please contact us with any COVID-19 queries at MACH-COVIDtrials@unimelb.edu.au
MACH COVID-19 Activities
The Committee meet regularly to deploy its wide-ranging expertise to make a consensus recommendation as to which interventional clinical trials are of the highest priority to support MACH-affiliated health services.
Current recommendations are found below with information updated after each Committee meeting:
Factors favouring an assessment as a highest priority trial may include:
Funding from the NHMRC/MRFF
An adaptive design
An opportunity to join an outstanding quality international study
Studies that nest in biobankable or diagnostic material
Studies addressing a particular local need
MACH invites partner Research Offices to alert us to studies that are sufficiently advanced to be seeking ethics and governance approval and other queries related to COVID-19 research and trials (including non-clinical trials).
Streamlining ethical approval across MACH
Research Managers (through the statewide Hospital Research Managers Committee) have agreed to fast-track COVID-19 trials through Human Research Ethics Committee (HREC) approval and are reviewing the use of the framework of National Mutual Acceptance (NMA).
Recent News & Media